عب
عمر بدران
لم تتم إضافة الموقع
4 أغسطس 2026
Neutrophil-to-lymphocyte ratio in HR+/HER2− metastatic breast cancer treated with CDK4/6 inhibitors
Retrospective cohort study evaluating whether baseline neutrophil-to-lymphocyte ratio is associated with CDK4/6 inhibitor-related toxicities and survival outcomes in patients with HR+/HER2− metastatic breast cancer treated with palbociclib or ribociclib.
اقرأ المقال